Finance

Quince Therapeutics Stock Dives as NEAT Trial Misses Significance

Quince Therapeutics' stock fell after topline NEAT Phase 3 results for eDSP in Ataxia-Telangiectasia missed both primary and a key secondary endpoint. The market cited a 2.22% premarket drop to $0.262, and unverified chatter of a near-90% intraday plunge circulated.

📅 January 30, 2026
⏱️ 2 min read
Quince Therapeutics Stock Dives as NEAT Trial Misses Significance

Key Takeaways

  • NEAT topline results missed primary RMICARS (p=0.0851) and key secondary CGI-S (p=0.522).
  • Enrollment: 105 participants (83 aged 6-9; 22 aged 10+) in the pivotal trial.
  • eDSP was generally well tolerated with pruritus and pyrexia as common adverse events; no clinically meaningful safety concerns identified.
  • Long-term safety data from BPNA 2026 poster suggest stable growth and no corticosteroid-related toxicities; no confirmed adrenal insufficiency.
  • Premarket price action showed a 2.22% drop to $0.262; unverified reports of a ~90% intraday decline should be treated with caution.

People Involved

  • No specific individuals mentioned

Entities Involved

  • Quince Therapeutics Inc. (QNCX)Developer of eDSP for Ataxia-Telangiectasia
  • British Paediatric Neurology Association (BPNA)Organization hosting the 2026 conference poster on pediatric safety data

MarketMoodz Analysis

The topline results cast a shadow over NEAT’s near-term regulatory prospects. Missing both the primary RMICARS endpoint (p=0.0851) and the CGI-S secondary endpoint (p=0.522) reduces the likelihood of a near-term FDA approval and heightens questions about the program's commercial potential.

From a historical view, biotech stocks often swing sharply on pivotal readouts, especially in rare-disease programs where single endpoints drive outcomes. The data here suggest limited efficacy signals, though the safety profile—while not a savior—may affect future trial designs or combination strategies.

Investors should watch for management commentary on any follow-up efficacy analyses, potential readouts from other cohorts, and funding runway. The BPNA safety data add a potential tailwind for risk management, but they do little to offset the lack of efficacy signals in the NEAT study.

Source: Original Article

Get AI-Powered Market Insights

Stay ahead of market-moving events with our real-time analysis and stock ratings.

Start Your Free Trial